Research Study: ARIES HM3
heart failure
Study Sponsor: Abbott Medical Devices
Study Investigator: Peter Eckman, MD
Study Contact: Kari Thomas
Every research study comes with its own unique risks and benefits; the study team will assess whether you’re an eligible candidate and ensure you’re provided with all the information you need to decide if participating is right for you.
About this Study:

Prospective, randomized, double-blinded, placebo-controlled clinical investigation of advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K antagonist with aspirin versus vitamin K antagonist with placebo.
Eligibility Criteria:

  • Subject will receive the HeartMate 3 per standard of care (SOC) in accordance with the approved indications for use in the country of implant.
  • Subject will receive the HeartMate 3 as their first durable VAD.
  • Subject must provide written informed consent prior to any clinical investigation related procedure.
  • In female patients of child bearing capability, subject will not be currently pregnant or breastfeeding and on appropriate contraception.

Interested in participating in this study?

Reach out to the study contact directly, or fill out this form and we will contact you and assess whether you are an eligible candidate!